# S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

> **NCT00937417** · PHASE1 · WITHDRAWN · sponsor: **SWOG Cancer Research Network**

## Conditions studied

- Breast Cancer
- Head and Neck Cancer
- Lung Cancer
- Prostate Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** docetaxel
- **DRUG:** vandetanib
- **GENETIC:** proteomic profiling
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00937417
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn because SWOG no longer pursuing this study at this time
- **Last updated:** 2017-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937417, "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00937417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*